Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
September 06, 2023 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it...
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
August 03, 2023 09:07 ET
|
Cassava Sciences, Inc.
Results of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023.Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an...
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
July 05, 2023 09:15 ET
|
Cassava Sciences, Inc.
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild Alzheimer’s Disease.In Mild Alzheimer’s,...
New Research Shows Simufilam Suppresses Overactive mTOR
June 27, 2023 09:15 ET
|
Cassava Sciences, Inc.
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease.Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect.Research is Published in Frontiers in Aging, a Peer-reviewed...
New Publication Highlights Basic Science Supporting Simufilam
June 12, 2023 09:15 ET
|
Cassava Sciences, Inc.
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research, a Peer-Reviewed Journal. AUSTIN, Texas,...
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
June 01, 2023 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has...
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
May 11, 2023 09:15 ET
|
Cassava Sciences, Inc.
The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease.Primary Outcome Measures Are Safety and Change in Cognition...
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
May 08, 2023 09:15 ET
|
Cassava Sciences, Inc.
New in vitro data from Europe show that simufilam can reverse altered filamin A protein (FLNA) in pituitary tumor cells, leading to improved cell signaling.Data suggest FLNA is a central factor...
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
May 01, 2023 09:00 ET
|
Cassava Sciences, Inc.
Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still expected Q4 2023.$187.5 Million Cash and Cash Equivalents at...
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
April 26, 2023 09:12 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier,...